Liu Zhihua for China Daily writes (excerpted);

The company has been developing an immune cell therapy product based on a method called Expanding Activated Lymphocytes to treat solid tumor, and the clinical trial is designed to access the therapy’s ability to prevent recurrence after radical surgery of liver cancer, one of the top cancer killers in China.  The trial aims to recruit 272 patients, making it the largest of its kind, and will provide policymakers and regulators objective and informative data to promote the development of immune cell therapy technology in China, the company said.

Click here to read the entire article